In vitro models of neuromuscular junctions and their potential for novel drug discovery and development

References

• Wu H, Xiong WC, Mei L. To build a synapse: signaling pathways in neuromuscular junction assembly. Dev Camb Engl. 2010;137:1017–1033.
   PubMed Web of Science ®Google Scholar
• Punga AR, Ruegg MA. Signaling and aging at the neuromuscular synapse: lessons learnt from neuromuscular diseases. Curr Opin Pharmacol. 2012;12:340–346.
   PubMed Web of Science ®Google Scholar
• Cifuentes-Diaz C, Nicole S, Velasco ME, et al. Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. Hum Mol Genet. 2002;11:1439–1447.
   PubMed Web of Science ®Google Scholar
• Kariya S, Park G-H, Maeno-Hikichi Y, et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet. 2008;17:2552–2569.
   PubMed Web of Science ®Google Scholar
• Kong L, Wang X, Choe DW, et al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci Off J Soc Neurosci. 2009;29:842–851.
   PubMed Web of Science ®Google Scholar
• Moloney EB, de Winter F, Verhaagen J. ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front Neurosci. 2014;8:252.
   Web of Science ®Google Scholar
• Murray LM, Talbot K, Gillingwater TH. Review: neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy. Neuropathol Appl Neurobiol. 2010;36:133–156.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Freire M, de Cabo R, Studenski SA, et al. The neuromuscular junction: aging at the crossroad between nerves and muscle. Front Aging Neurosci. 2014;6:208.
   PubMed Web of Science ®Google Scholar
• Taetzsch T, Valdez G. NMJ maintenance and repair in aging. Curr Opin Physiol. 2018;4:57–64.
   PubMed Web of Science ®Google Scholar
• Webster RG. Animal models of the neuromuscular junction, vitally informative for understanding function and the molecular mechanisms of congenital myasthenic syndromes. Int J Mol Sci. 2018;19(5):1326.
   PubMed Web of Science ®Google Scholar
• Jones RA, Harrison C, Eaton SL, et al. Cellular and molecular anatomy of the human neuromuscular junction. Cell Rep. 2017;21:2348–2356.
   PubMed Web of Science ®Google Scholar
• Burridge PW, Matsa E, Shukla P, et al. Chemically defined generation of human cardiomyocytes. Nat Methods. 2014;11:855–860.
   PubMed Web of Science ®Google Scholar
• Chunhui X, Shailaja P, Namitha R, et al. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res. 2002;91:501–508.
   PubMed Web of Science ®Google Scholar
• Jianhua Z, Wilson Gisela F, Soerens Andrew G, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104:e30–e41.
   PubMed Web of Science ®Google Scholar
• Hay DC, Fletcher J, Payne C, et al. Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci. 2008;105:12301–12306.
   PubMed Web of Science ®Google Scholar
• Si‐Tayeb K, Noto FK, Nagaoka M, et al. Highly efficient generation of human hepatocyte–like cells from induced pluripotent stem cells. Hepatology. 2010;51:297–305.
   PubMed Web of Science ®Google Scholar
• Guo X, Greene K, Akanda N, et al. In vitro differentiation of functional human skeletal myotubes in a defined system. Biomater Sci. 2014;2:131–138.
   PubMed Web of Science ®Google Scholar
• Rao L, Qian Y, Khodabukus A, et al. Engineering human pluripotent stem cells into a functional skeletal muscle tissue. Nat Commun. 2018;9:1–12.
   PubMed Web of Science ®Google Scholar
• Hu B-Y, Zhang S-C. Differentiation of spinal motor neurons from pluripotent human stem cells. Nat Protoc. 2009;4:1295–1304.
   PubMed Web of Science ®Google Scholar
• Maury Y, Côme J, Piskorowski RA, et al. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat Biotechnol. 2015;33:89–96.
   PubMed Web of Science ®Google Scholar
• Du Z-W, Chen H, Liu H, et al. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat Commun. 2015;6:1–9.
   Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872.
   PubMed Web of Science ®Google Scholar
• Corti S, Nizzardo M, Simone C, et al. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med. 2012;4:165ra162.
   PubMed Web of Science ®Google Scholar
• Ebert AD, Yu J, Rose FF, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2009;457:277–280.
   PubMed Web of Science ®Google Scholar
• Sareen D, Ebert AD, Heins BM, et al. Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PloS One. 2012;7:e39113.
   PubMed Web of Science ®Google Scholar
• Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321:1218–1221.
   PubMed Web of Science ®Google Scholar
• Sareen D, O’Rourke JG, Meera P, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. 2013;5:208ra149.
   PubMed Web of Science ®Google Scholar
• Serio A, Bilican B, Barmada SJ, et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc Natl Acad Sci U S A. 2013;110:4697–4702.
   PubMed Web of Science ®Google Scholar
• Kiskinis E, Sandoe J, Williams LA, et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell. 2014;14:781–795.
   PubMed Web of Science ®Google Scholar
• Devlin A-C, Burr K, Borooah S, et al. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat Commun. 2015;6:1–12.
   Web of Science ®Google Scholar
• Sances S, Bruijn LI, Chandran S, et al. Modeling ALS with motor neurons derived from human induced pluripotent stem cells. Nat Neurosci. 2016;19:542–553.
   PubMed Web of Science ®Google Scholar
• Peterson ER, Crain SM. Regeneration and innervation in cultures of adult mammalian skeletal muscle coupled with fetal rodent spinal cord. Exp Neurol. 1972;36:136–159.
   PubMed Web of Science ®Google Scholar
• Das M, Rumsey JW, Bhargava N, et al. A defined long-term in vitro tissue engineered model of neuromuscular junctions. Biomaterials. 2010;31:4880–4888.
   PubMed Web of Science ®Google Scholar
• Chipman PH, Zhang Y, Rafuse VF. A stem-cell based bioassay to critically assess the pathology of dysfunctional neuromuscular junctions. PloS One. 2014;9:e91643.
   PubMed Web of Science ®Google Scholar
• Li X-J, Du Z-W, Zarnowska ED, et al. Specification of motoneurons from human embryonic stem cells. Nat Biotechnol. 2005;23:215–221.
   PubMed Web of Science ®Google Scholar
• Guo X, Das M, Rumsey J, et al. Neuromuscular junction formation between human stem-cell-derived motoneurons and rat skeletal muscle in a defined system. Tissue Eng Part C Methods. 2010;16:1347–1355.
   PubMed Web of Science ®Google Scholar
• Guo X, Gonzalez M, Stancescu M, et al. Neuromuscular junction formation between human stem cell-derived motoneurons and human skeletal muscle in a defined system. Biomaterials. 2011;32:9602–9611.
   PubMed Web of Science ®Google Scholar
• Demestre M, Orth M, Föhr KJ, et al. Formation and characterisation of neuromuscular junctions between hiPSC derived motoneurons and myotubes. Stem Cell Res. 2015;15:328–336.
   PubMed Web of Science ®Google Scholar
• Campenot RB. Local control of neurite development by nerve growth factor. Proc Natl Acad Sci U S A. 1977;74:4516–4519.
   PubMed Web of Science ®Google Scholar
• Jia M, Li M, Dunlap V, et al. The thrombin receptor mediates functional activity-dependent neuromuscular synapse reduction via protein kinase C activation in vitro. J Neurobiol. 1999;38:369–381.
   PubMedGoogle Scholar
• Nelson PG, Fields RD, Yu C, et al. Synapse elimination from the mouse neuromuscular junction in vitro: a non-hebbian activity-dependent process. J Neurobiol. 1993;24:1517–1530.
   PubMedGoogle Scholar
• Southam KA, King AE, Blizzard CA, et al. Microfluidic primary culture model of the lower motor neuron–neuromuscular junction circuit. J Neurosci Methods. 2013;218:164–169.
   PubMed Web of Science ®Google Scholar
• Park HS, Liu S, McDonald J, et al. Neuromuscular junction in a microfluidic device. 2013 35th Annu Int Conf IEEE Eng Med Biol Soc EMBC. 2013;2833–2835.
   Google Scholar
• Zahavi EE, Ionescu A, Gluska S, et al. A compartmentalized microfluidic neuromuscular co-culture system reveals spatial aspects of GDNF functions. J Cell Sci. 2015;128:1241–1252.
   PubMed Web of Science ®Google Scholar
• Santhanam N, Kumanchik L, Guo X, et al. Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics. Biomaterials. 2018;166:64–78.
   PubMed Web of Science ®Google Scholar
• Happe CL, Tenerelli KP, Gromova AK, et al. Mechanically patterned neuromuscular junctions-in-a-dish have improved functional maturation. Mol Biol Cell. 2017;28:1950–1958.
   PubMed Web of Science ®Google Scholar
• Luo B, Tian L, Chen N, et al. Electrospun nanofibers facilitate better alignment, differentiation, and long-term culture in an in vitro model of the neuromuscular junction (NMJ). Biomater Sci. 2018;6:3262–3272.
   PubMed Web of Science ®Google Scholar
• Madden L, Juhas M, Kraus WE, et al. Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs. eLife. 2015;4:e04885.
   PubMed Web of Science ®Google Scholar
• Okano T, Matsuda T. Tissue engineered skeletal muscle: preparation of highly dense, highly oriented hybrid muscular tissues. Cell Transplant. 1998;7:71–82.
   PubMed Web of Science ®Google Scholar
• Powell CA, Smiley BL, Mills J, et al. Mechanical stimulation improves tissue-engineered human skeletal muscle. Am J Physiol-Cell Physiol. 2002;283:C1557–C1565.
   PubMed Web of Science ®Google Scholar
• Ronaldson-Bouchard K, Ma SP, Yeager K, et al. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature. 2018;556:239–243.
   PubMed Web of Science ®Google Scholar
• Thavandiran N, Dubois N, Mikryukov A, et al. Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. Proc Natl Acad Sci. 2013;110:E4698–E4707.
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Kato-Negishi M, Onoe H, et al. Three-dimensional neuron-muscle constructs with neuromuscular junctions. Biomaterials. 2013;34:9413–9419.
   PubMed Web of Science ®Google Scholar
• Smith AST, Passey SL, Martin NRW, et al. Creating interactions between tissue-engineered skeletal muscle and the peripheral nervous system. Cells Tissues Organs. 2016;202:143–158.
   PubMed Web of Science ®Google Scholar
• Smith AST, Long CJ, Pirozzi K, et al. A functional system for high-content screening of neuromuscular junctions in vitro. Technology. 2013;1:37–48.
   PubMedGoogle Scholar
• Afshar Bakooshli M, Lippmann ES, Mulcahy B, et al. A 3D culture model of innervated human skeletal muscle enables studies of the adult neuromuscular junction. eLife. 2019;8:e44530.
   Web of Science ®Google Scholar
• Boyden ES, Zhang F, Bamberg E, et al. Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci. 2005;8:1263–1268.
   PubMed Web of Science ®Google Scholar
• Steinbeck JA, Jaiswal MK, Calder EL, et al. Functional connectivity under optogenetic control allows modeling of human neuromuscular disease. Cell Stem Cell. 2016;18:134–143.
   PubMed Web of Science ®Google Scholar
• Uzel SGM, Platt RJ, Subramanian V, et al. Microfluidic device for the formation of optically excitable, three-dimensional, compartmentalized motor units. Sci Adv. 2016;2:e1501429.
   PubMed Web of Science ®Google Scholar
• Osaki T, Uzel SGM, Kamm RD. Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons. Sci Adv. 2018;4:eaat5847.
   PubMed Web of Science ®Google Scholar
• Vila OF, Uzel SGM, Ma SP, et al. Quantification of human neuromuscular function through optogenetics. Theranostics. 2019;9:1232–1246.
   PubMed Web of Science ®Google Scholar
• Kusner LL, Kaminski HJ, Soltys J. Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert Rev Clin Immunol. 2008;4:43–52.
   PubMed Web of Science ®Google Scholar
• Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kitaoka S, Egawa N, et al. Modeling the early phenotype at the neuromuscular junction of spinal muscular atrophy using patient-derived iPSCs. Stem Cell Rep. 2015;4:561–568.
   Web of Science ®Google Scholar
• Blasco H, Mavel S, Corcia P, et al. The glutamate hypothesis in ALS: pathophysiology and drug development. Current Medicinal Chemistry. 2014;21(31):3551–3575.
   Google Scholar
• Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis. Ann Neurol. 1990;28:3–8.
   PubMed Web of Science ®Google Scholar
• Charoensook SN, Williams DJ, Chakraborty S, et al. Bioreactor model of neuromuscular junction with electrical stimulation for pharmacological potency testing. Integr Biol Quant Biosci Nano Macro. 2017;9:956–967.
   Google Scholar
• Macia E, Ehrlich M, Massol R, et al. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell. 2006;10:839–850.
   PubMed Web of Science ®Google Scholar
• Dressler D, Saberi FA. Botulinum toxin: mechanisms of action. Eur Neurol. 2005;53:3–9.
   PubMed Web of Science ®Google Scholar
• Huber A, France RM, Riccalton-Banks L, et al. The intercostal NMJ assay: a new alternative to the conventional LD50 assay for the determination of the therapeutic potency of botulinum toxin preparations. Altern Lab Anim ATLA. 2008;36:141–152.
   PubMed Web of Science ®Google Scholar
• Blount P, Merlie JP. Molecular basis of the two nonequivalent ligand binding sites of the muscle nicotinic acetylcholine receptor. Neuron. 1989;3:349–357.
   PubMed Web of Science ®Google Scholar
• Sine SM. Molecular dissection of subunit interfaces in the acetylcholine receptor: identification of residues that determine curare selectivity. Proc Natl Acad Sci U S A. 1993;90:9436–9440.
   PubMed Web of Science ®Google Scholar
• Chang CC, Lee CY. Isolation of neurotoxins from the venom of bungarus multicinctus and their modes of neuromuscular blocking action. Arch Int Pharmacodyn Ther. 1963;144:241–257.
   PubMedGoogle Scholar
• McArdle JJ, Lentz TL, Witzemann V, et al. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 1999;289:543–550.
   PubMed Web of Science ®Google Scholar
• Rapamycin Treatment for ALS. Full Text View - ClinicalTrials.gov. [cited 2019 Sep 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03359538.
   Google Scholar
• Mandrioli J, D’Amico R, Zucchi E, et al. Rapamycin treatment for amyotrophic lateral sclerosis: protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine (Baltimore). 2018;97:e11119.
   PubMed Web of Science ®Google Scholar
• Phase 1 dose escalation study of bosutinib in patients with Amyotrophic Lateral Sclerosis (ALS). [cited 2019 Sep 12]. Available from: https://rctportal.niph.go.jp/en/detail?trial_id=jRCT2051190001.
   Google Scholar
• Mars T, Yu KJ, Tang XM, et al. Differentiation of glial cells and motor neurons during the formation of neuromuscular junctions in cocultures of rat spinal cord explant and human muscle. J Comp Neurol. 2001;438:239–251.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Whellan DJ, Berridge BR, et al. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the critical path initiative. Am Heart J. 2009;158:317–326.
   PubMed Web of Science ®Google Scholar
• Boos JA, Misun PM, Michlmayr A, et al. Microfluidic multitissue platform for advanced embryotoxicity testing In Vitro. Adv Sci. 2019;6:1900294.
   Web of Science ®Google Scholar
• Kimura H, Sakai Y, Fujii T. Organ/body-on-a-chip based on microfluidic technology for drug discovery. Drug Metab Pharmacokinet. 2018;33:43–48.
   PubMed Web of Science ®Google Scholar